ATE520031T1 - Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen - Google Patents

Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen

Info

Publication number
ATE520031T1
ATE520031T1 AT02784318T AT02784318T ATE520031T1 AT E520031 T1 ATE520031 T1 AT E520031T1 AT 02784318 T AT02784318 T AT 02784318T AT 02784318 T AT02784318 T AT 02784318T AT E520031 T1 ATE520031 T1 AT E520031T1
Authority
AT
Austria
Prior art keywords
breast cancer
ibc
invasive
aplified
oncogen
Prior art date
Application number
AT02784318T
Other languages
English (en)
Inventor
Kornelia Polyak
Pankaj Seth
Dale Porter
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE520031T1 publication Critical patent/ATE520031T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02784318T 2001-10-26 2002-10-28 Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen ATE520031T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34315401P 2001-10-26 2001-10-26
US35630102P 2002-02-12 2002-02-12
PCT/US2002/034499 WO2003035848A1 (en) 2001-10-26 2002-10-28 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer

Publications (1)

Publication Number Publication Date
ATE520031T1 true ATE520031T1 (de) 2011-08-15

Family

ID=26993355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784318T ATE520031T1 (de) 2001-10-26 2002-10-28 Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen

Country Status (6)

Country Link
EP (1) EP1438388B1 (de)
JP (1) JP2005511552A (de)
AT (1) ATE520031T1 (de)
AU (1) AU2002348101A1 (de)
CA (1) CA2464700C (de)
WO (1) WO2003035848A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624687D0 (en) * 2006-12-11 2007-01-17 Univ Aston Treatment of cachexia
WO2008099928A1 (ja) * 2007-02-16 2008-08-21 Jin-Pyo Lee 蛋白質分解酵素活性を調節する作用を有する胎盤蛋白質及びその関連遺伝子
WO2012009577A2 (en) 2010-07-14 2012-01-19 Alper Biotech, Llc Monoclonal antibodies against pcbp-1 antigens, and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834192A (en) * 1996-04-05 1998-11-10 Incyte Pharmaceuticals, Inc. Human cachexia associated protein
AU4199597A (en) * 1996-09-09 1998-04-02 Novo Nordisk A/S A cdna and peptide with relation to cancer and weight loss

Also Published As

Publication number Publication date
EP1438388B1 (de) 2011-08-10
CA2464700A1 (en) 2003-05-01
JP2005511552A (ja) 2005-04-28
CA2464700C (en) 2013-12-10
EP1438388A1 (de) 2004-07-21
AU2002348101A1 (en) 2003-05-06
WO2003035848A9 (en) 2005-01-20
EP1438388A4 (de) 2005-11-23
WO2003035848A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
HK1148783A1 (zh) 用於乳房腺的預後的基因表達標記
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
WO2003087831A3 (en) Proteins involved in breast cancer
EP1700120A4 (de) Marker für neuromyelitis optica
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2003065006A3 (en) Methods and compositions for treating cancer
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2009087462A3 (en) Ephrin type-a receptor 10 protein
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
WO2004031414A3 (en) Method for diagnosing prostate cancer
HK1056692A1 (en) Proteins
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2005106039A8 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
AU2002367317A1 (en) Psoriasin expression by breast epithelial cells
DE69931644D1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties